Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likel
Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.
350000 (raw units)
price
1
calls / 30d
1
unique payers
2026-08-20
updated
Provider
clinicalintelpulse.theaslangroupllc.com · discovered, not yet claimed by its owner
Payment (x402 accepts[])
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "350000",
"maxTimeoutSeconds": 604900
},
{
"scheme": "exact",
"network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
"payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
"asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:137",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:42161",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:480",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:143",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:196",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:999",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
"payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
"asset": "31566704",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "XRP",
"amount": "350000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "524C555344000000000000000000000000000000",
"amount": "0.35",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:56",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
"amount": "350000000000000000",
"maxTimeoutSeconds": 300
}
]Output schema
{
"bazaar": {
"info": {
"input": {
"method": "GET",
"queryParams": {
"condition": "Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"",
"deal_type": "acquisition | licensing | both (default: both)",
"lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
"stage": "phase2 | phase3 | both (default: both)"
},
"type": "http"
},
"output": {
"example": {
"acquisition_targets": [
{
"asset": "Mazdutide (IBI362)",
"clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
"company": "Innovent Biologics (China)",
"deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
"deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
"estimated_deal_value_usd_m": "800-2000",
"mechanism": "GLP-1/glucagon dual agonist",
"probability": "High",
"risks": [
"China geopolitical risk for IP transfer",
"Phase 3 US/EU data needed before deal close"
],
"stage": "PHASE3"
}
],
"deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
"licensing_opportunities": [
{
"asset": "CT-388 (dual GLP-1/GIP)",
"company": "Carmot Therapeutics (acq. Roche)",
"estimated_license_value_usd_m": "300-800",
"notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm"
}
],
"market_context": {
"approved_leaders": [
"Semaglutide (Novo Nordisk — Wegovy)",
"Tirzepatide (Lilly — Zepbound)"
],
"big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
"total_addressable_market_usd_bn": 100
},
"query_summary": {
"as_of": "2026-06-07",
"condition": "Obesity",
"deal_type": "both",
"stage": "both"
},
"recent_deal_comps": [
{
"deal": "Roche / Carmot Therapeutics",
"mechanism": "GLP-1 peptide",
"stage": "PHASE1/2",
"value_usd_bn": 2.7,
"year": 2023
},
{
"deal": "AstraZeneca / Eccogene",
"mechanism": "Small-molecule GLP-1",
"stage": "PHASE2",
"value_usd_bn": 1.85,
"year": 2024
},
{
"deal": "Amgen / ChemoCentryx",
"mechanism": "C5aR1",
"stage": "Approved",
"value_usd_bn": 3.7,
"year": 2022
}
]
},
"type": "json"
}
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"properties": {
"input": {
"additionalProperties": false,
"properties": {
"method": {
"enum": [
"GET",
"HEAD",
"DELETE"
],
"type": "string"
},
"queryParams": {
"properties": {
"condition": {
"type": "string"
},
"deal_type": {
"type": "string"
},
"lang": {
"type": "string"
},
"stage": {
"type": "string"
}
},
"type": "object"
},
"type": {
"const": "http",
"type": "string"
}
},
"required": [
"type",
"method"
],
"type": "object"
},
"output": {
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}
},
"required": [
"input"
],
"type": "object"
}
},
"builder-code": {
"info": {
"a": "bc_gxy6qn5p"
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"additionalProperties": false,
"properties": {
"a": {
"description": "App builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"s": {
"description": "Service builder codes",
"items": {
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"type": "array"
},
"w": {
"description": "Wallet builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
}
},
"type": "object"
}
}
}Use it
curl
curl "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal" # -> 402 Payment Required, accepts[] lists how to pay # retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paid
JavaScript
const res = await fetch("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}Python
import httpx
res = httpx.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerMachine-readable
Everything on this page is also available as clean JSON at /resources/4546.json, and this resource appears in /discovery/resources and /discovery/search.